SLAMF6 in Health and Disease: Implications for Therapeutic Targeting

Overview

Journal Clin Immunol

Specialty Allergy & Immunology

Date 2018 Oct 27

PMID 30366106

Citations 9

Authors

Burcu Yigit

Ninghai Wang

Roland W Herzog

Cox Terhorst

Affiliations

Soon will be listed here.

Citing Articles

Endometrial regeneration cell-derived exosomes loaded with siSLAMF6 inhibit cardiac allograft rejection through the suppression of desialylation modification.

Xu Y, Ren S, Wang H, Qin Y, Liu T, Sun C Cell Mol Biol Lett. 2024; 29(1):128.

PMID: 39354345 PMC: 11443917. DOI: 10.1186/s11658-024-00645-y.

Bioinformatic analysis of hippocampal histopathology in Alzheimer's disease and the therapeutic effects of active components of traditional Chinese medicine.

Zhiyan C, Min Z, Yida D, Chunying H, Xiaohua H, Yutong L Front Pharmacol. 2024; 15:1424803.

PMID: 39221152 PMC: 11362046. DOI: 10.3389/fphar.2024.1424803.

RT-DOb, a switch gene for the gene pair {Csf1r, Milr1}, can influence the onset of Alzheimer's disease by regulating communication between mast cell and microglia.

Khayer N, Motamed N, Marashi S, Goshadrou F PLoS One. 2023; 18(7):e0288134.

PMID: 37410787 PMC: 10325119. DOI: 10.1371/journal.pone.0288134.

Characterization of Ly108-H1 Signaling Reveals Ly108-3 Expression and Additional Strain-Specific Differences in Lupus Prone Mice.

Rietdijk S, Keszei M, Castro W, Terhorst C, Abadia-Molina A Int J Mol Sci. 2023; 24(5).

PMID: 36902453 PMC: 10003074. DOI: 10.3390/ijms24055024.

N6-Methyladenosine-Related Gene Signature Associated With Monocyte Infiltration Is Clinically Significant in Gestational Diabetes Mellitus.

Du R, Li L, Wang Y Front Endocrinol (Lausanne). 2022; 13:853857.

PMID: 35370940 PMC: 8971567. DOI: 10.3389/fendo.2022.853857.

References

Kumar S, Lee J, Lahuerta J, MORGAN G, Richardson P, Crowley J . Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2011; 26(1):149-57. PMC: 4109061. DOI: 10.1038/leu.2011.196. View

Marom A, Barak A, Kramer M, Lewinsky H, Binsky-Ehrenreich I, Cohen S . CD84 mediates CLL-microenvironment interactions. Oncogene. 2016; 36(5):628-638. DOI: 10.1038/onc.2016.238. View

De Calisto J, Wang N, Wang G, Yigit B, Engel P, Terhorst C . SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF Receptors. Front Immunol. 2014; 5:186. PMC: 4005954. DOI: 10.3389/fimmu.2014.00186. View

Yusuf I, Kageyama R, Monticelli L, Johnston R, DiToro D, Hansen K . Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150). J Immunol. 2010; 185(1):190-202. PMC: 2913439. DOI: 10.4049/jimmunol.0903505. View

Tassi I, Colonna M . The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol. 2005; 175(12):7996-8002. DOI: 10.4049/jimmunol.175.12.7996. View

Ramsay A, Clear A, Fatah R, Gribben J . Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012; 120(7):1412-21. PMC: 3423779. DOI: 10.1182/blood-2012-02-411678. View

Cuenca M, Romero X, Sintes J, Terhorst C, Engel P . Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses. J Immunol. 2015; 196(2):726-37. PMC: 4707085. DOI: 10.4049/jimmunol.1501266. View

Kitada S, Zapata J, Andreeff M, Reed J . Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999; 106(4):995-1004. DOI: 10.1046/j.1365-2141.1999.01642.x. View

Riches J, Davies J, McClanahan F, Fatah R, Iqbal S, Agrawal S . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2012; 121(9):1612-21. PMC: 3587324. DOI: 10.1182/blood-2012-09-457531. View

10.

Gordiienko I, Shlapatska L, Kholodniuk V, Sklyarenko L, Gluzman D, Clark E . The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling. PLoS One. 2017; 12(10):e0185940. PMC: 5628907. DOI: 10.1371/journal.pone.0185940. View

11.

Da Roit F, Engelberts P, Taylor R, Breij E, Gritti G, Rambaldi A . Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2014; 100(1):77-86. PMC: 4281316. DOI: 10.3324/haematol.2014.107011. View

12.

Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand A . Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996; 92(1):97-103. DOI: 10.1046/j.1365-2141.1996.00305.x. View

13.

Isomaki P, Aversa G, Cocks B, Luukkainen R, Saario R, TOIVANEN P . Increased expression of signaling lymphocytic activation molecule in patients with rheumatoid arthritis and its role in the regulation of cytokine production in rheumatoid synovium. J Immunol. 1997; 159(6):2986-93. View

14.

Brown M, Boles K, van der Merwe P, Kumar V, Mathew P, Barclay A . 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med. 1998; 188(11):2083-90. PMC: 2212392. DOI: 10.1084/jem.188.11.2083. View

15.

Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-5. View

16.

Del Valle J, Engel P, Martin M . The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). J Biol Chem. 2003; 278(19):17430-7. DOI: 10.1074/jbc.M301569200. View

17.

van Driel B, Liao G, Engel P, Terhorst C . Responses to Microbial Challenges by SLAMF Receptors. Front Immunol. 2016; 7:4. PMC: 4718992. DOI: 10.3389/fimmu.2016.00004. View

18.

Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, DArena G . CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia. 2010; 24(5):958-69. DOI: 10.1038/leu.2010.36. View

19.

van de Donk N, Kamps S, Mutis T, Lokhorst H . Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2011; 26(2):199-213. DOI: 10.1038/leu.2011.214. View

20.

Yigit B, Halibozek P, Chen S, OKeeffe M, Arnason J, Avigan D . A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget. 2016; 7(18):26346-60. PMC: 5041984. DOI: 10.18632/oncotarget.8378. View